US patent for BCR Diagnostic's amplification technology:
This article was originally published in Clinica
Rhode Island-based BCR Diagnostics (US) has been granted a US patent for its Bacterial Chain Reaction amplification and visualisation technology. The BCR system amplifies and visualises signals from biomolecular probes such as antibodies, binding proteins and nucleic acid probes by using micro-organisms as nanodevices. The company believes the BCR technology could be useful in, among other things, cancer cell detection in blood and bone marrow, in situ PCR, ELISA and blotting techniques. President Boris Rotman says his company plans to expand the applications in other diagnostic tests through licensing out the technology.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.